---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-030315"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-09-14T20:00:15+00:00"
generated_at: "2026-09-14T20:02:43.780424+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Moleculin to present new Annamycin data at AACR pancreatic cancer conference and two European scientific meetings

## Summary
- Three September 2026 presentations examine Annamycin tissue distribution, topoisomerase II inhibition, and CD8+ T cell-mediated antitumor activity.
- Presentations include Sept 25-28 AACR Pancreatic Cancer Conference in San Diego, plus Polish meetings on Sept 9-12 and Sept 14.
- Waldemar Priebe (MD Anderson) presents two talks; Angela Alistar (Atlantic Health) presents AACR abstract on pancreatic cancer.
- MIRACLE trial in relapsed/refractory AML remains the primary development focus and basis of near-term milestones.
- AACR abstract under embargo until publication on Sept 25, 2026 at 1:00 p.m. ET.

## SEC filing metadata
- accession: 0001437749-26-030315
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-09-14T20:00:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926030315/0001437749-26-030315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926030315/mbrx20260911_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-030315
- JSON: https://secwatch.observer/filing/0001437749-26-030315.json
- Plain text: https://secwatch.observer/filing/0001437749-26-030315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.